HIV Policy

For 340B-covered entities, core to the challenge of navigating a changing and uncertain policy landscape is the complexity of how multiple variables interact differently with each covered health care entity based on its unique makeup of services, funding, patient population, and payer mix. This toolkit aims to assist 340B covered entities in understanding their current areas of funding stability and where they are vulnerable, and to plan for the future.

Read More
HIV Policy
Navigating changes to the 340B drug pricing program: a toolkit for HIV-related healthcare entities in California

October 4, 2024

In light of proposed and actual changes in Federal and State policy that have the potential to affect the 340B program, we conducted a rapid response study, exploring the impact to facilities that serve people living with or at risk for HIV. As a companion to the Navigating 340B Toolkit, this Explainer takes a closer look at the answers to these three questions: 1. How does 340B work? 2. What is the relationship between 340B and HIV services? 3. What are the current factors impacting 340B revenue for HIV clinical and service organizations?

Read More
HIV Policy
Navigating 340B amidst policy changes: an explainer

October 4, 2024

A new paper published in JAIDS finds that pharmacists could play a key role in providing long-acting injectable pre-exposure prophylaxis (PrEP) for HIV prevention. In a mixed methods analysis of survey and interview data, CHPRC researchers found that many pharmacists would be willing to administer injectable PrEP if provided with training, compensation, and a private room. However, pharmacists may require additional resources and policy support to make widespread implementation feasible.

Read More
HIV Policy
A mixed methods evaluation of pharmacists’ readiness to provide long-acting injectable HIV pre-exposure prophylaxis in California

September 25, 2024

Infographic Pharmacist-initiated naloxone and syringe furnishing in California January 18, 2024 Infographic highlighting some of the results from the 2022 California Pharmacist Survey. Pharmacists were asked about their furnishing of naloxone and syringe without an outside provider’s prescription. Includes some policy implications.   — Image by Freepik Download Authors Northern California HIV/AIDS Policy Research Center

Read More
HIV Policy
Pharmacist-initiated naloxone and syringe furnishing in California

January 18, 2024

Policy Brief Impact of the Inflation Reduction Act on the 340B Program December 4, 2023 The 340b program provides an important revenue source for many HIV clinics and facilities, but that revenue is dependent on drug pricing. The Inflation Reduction Act of 2022 introduced provisions to curb drug pricing. Our modeling suggests that 340b revenues […]

Read More
HIV Policy
Impact of the Inflation Reduction Act on the 340B Program

December 4, 2023